Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:37:07.475Z.
Calculation as of: 2026-10-06T15:37:07.475Z.
Quote observation: 2026-10-06T15:34:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
PE RATIO
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$116.57M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $116.57M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.58M | N/A |
| Genelux Corporation (GNLX)vs › | $116.36M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $116.31M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.96M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.39M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.61
Forward EPS (Est.)
$-0.90
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
